{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:32:33Z","timestamp":1789997553746,"version":"4.0.1"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2019,9,1]]},"DOI":"10.1001\/jamacardio.2019.2306","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T11:02:04Z","timestamp":1563361324000},"page":"846","source":"Crossref","is-referenced-by-count":109,"title":["Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older"],"prefix":"10.1001","volume":"4","author":[{"given":"Richard G.","family":"Bach","sequence":"first","affiliation":[{"name":"Cardiovascular Division, Department of Medicine, Washington University School of Medicine, St Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"White","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Division of Cardiology, Department of Medicine, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Lokhnygina","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Division of Cardiology, Department of Medicine, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin A.","family":"Bohula","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Califf","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Division of Cardiology, Department of Medicine, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Braunwald","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Cardiovascular Division, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Blazing","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Division of Cardiology, Department of Medicine, Duke University, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"hoi190039r1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ahj.2004.06.003","article-title":"Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE).","volume":"149","author":"Avezum","year":"2005","journal-title":"Am Heart J"},{"issue":"4","key":"hoi190039r2","first-page":"e38","article-title":"Heart disease and stroke statistics-2016 update: a report from the American Heart Association.","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"issue":"9976","key":"hoi190039r4","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"hoi190039r5","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0091-7435(84)90027-6","article-title":"Prognostic importance of cholesterol levels after myocardial infarction.","volume":"13","author":"Ulvenstam","year":"1984","journal-title":"Prev Med"},{"issue":"9","key":"hoi190039r6","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1001\/archinte.1993.00410090025004","article-title":"Total serum cholesterol levels and mortality risk as a function of age: a report based on the Framingham data.","volume":"153","author":"Kronmal","year":"1993","journal-title":"Arch Intern Med"},{"issue":"17","key":"hoi190039r7","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jama.1994.03520170045034","article-title":"Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years.","volume":"272","author":"Krumholz","year":"1994","journal-title":"JAMA"},{"issue":"9279","key":"hoi190039r8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0140-6736(01)05553-2","article-title":"Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study.","volume":"358","author":"Schatz","year":"2001","journal-title":"Lancet"},{"issue":"10","key":"hoi190039r9","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/S0735-1097(02)02477-4","article-title":"Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients.","volume":"40","author":"Allen Maycock","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"9753","key":"hoi190039r10","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial.","volume":"376","author":"Armitage","year":"2010","journal-title":"Lancet"},{"issue":"3","key":"hoi190039r11","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/(ISSN)1532-5415","article-title":"Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction.","volume":"54","author":"Foody","year":"2006","journal-title":"J Am Geriatr Soc"},{"issue":"10170","key":"hoi190039r12","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.","volume":"393","author":"Cholesterol Treatment Trialists\u2019 Collaboration","year":"2019","journal-title":"Lancet"},{"issue":"22","key":"hoi190039r13","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1161\/01.cir.0000436752.99896.22","article-title":"Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association.","volume":"128","author":"Fleg","year":"2013","journal-title":"Circulation"},{"key":"hoi190039r14","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines.","volume":"63","author":"Stone","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"hoi190039r15","first-page":"S0735-1097(18)39033-8","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Grundy","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"hoi190039r16","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","article-title":"2017 Focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways.","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"hoi190039r17","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"hoi190039r18","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.ahj.2008.07.023","article-title":"Rationale and design of IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimibe\/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.","volume":"156","author":"Cannon","year":"2008","journal-title":"Am Heart J"},{"issue":"5","key":"hoi190039r20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1001\/jamacardio.2017.0083","article-title":"Long-term safety and efficacy of achieving very low levels of low-density lipoprotein cholesterol: a prespecified analysis of the IMPROVE-IT trial.","volume":"2","author":"Giugliano","year":"2017","journal-title":"JAMA Cardiol"},{"issue":"21","key":"hoi190039r21","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1056\/NEJMoa0901316","article-title":"Early versus delayed, provisional eptifibatide in acute coronary syndromes.","volume":"360","author":"Giugliano","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"hoi190039r22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jacc.2016.11.070","article-title":"Atherothrombotic risk stratification and ezetimibe for secondary prevention.","volume":"69","author":"Bohula","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"hoi190039r23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.7326\/0003-4819-129-9-199811010-00002","article-title":"Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range: results of the Cholesterol and Recurrent Events (CARE) trial.","volume":"129","author":"Lewis","year":"1998","journal-title":"Ann Intern Med"},{"issue":"10","key":"hoi190039r24","doi-asserted-by":"publisher","first-page":"931","DOI":"10.7326\/0003-4819-134-10-200105150-00007","article-title":"Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial.","volume":"134","author":"Hunt","year":"2001","journal-title":"Ann Intern Med"},{"issue":"9346","key":"hoi190039r25","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"hoi190039r26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-147-1-200707030-00002","article-title":"Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease.","volume":"147","author":"Wenger","year":"2007","journal-title":"Ann Intern Med"},{"issue":"6","key":"hoi190039r27","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1161\/CIRCULATIONAHA.106.654756","article-title":"Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE).","volume":"115","author":"Deedwania","year":"2007","journal-title":"Circulation"},{"issue":"15","key":"hoi190039r28","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes.","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"hoi190039r29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1161\/STROKEAHA.107.488791","article-title":"Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease.","volume":"39","author":"Vergouwen","year":"2008","journal-title":"Stroke"},{"issue":"4","key":"hoi190039r30","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0002-9149(02)02489-X","article-title":"Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE).","volume":"90","author":"Steg","year":"2002","journal-title":"Am J Cardiol"},{"issue":"2","key":"hoi190039r31","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ahj.2010.12.014","article-title":"Use of intensive lipid-lowering therapy in patients hospitalized with acute coronary syndrome: an analysis of 65,396 hospitalizations from 344 hospitals participating in Get With The Guidelines (GWTG).","volume":"161","author":"Javed","year":"2011","journal-title":"Am Heart J"},{"issue":"15","key":"hoi190039r32","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1001\/jama.291.15.1864","article-title":"Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox.","volume":"291","author":"Ko","year":"2004","journal-title":"JAMA"},{"issue":"15","key":"hoi190039r33","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"issue":"48","key":"hoi190039r34","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1093\/eurheartj\/ehw377","article-title":"The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial.","volume":"37","author":"Eisen","year":"2016","journal-title":"Eur Heart J"},{"issue":"25","key":"hoi190039r35","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1161\/CIRCULATIONAHA.117.029095","article-title":"Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).","volume":"136","author":"Bohula","year":"2017","journal-title":"Circulation"},{"key":"hoi190039r3","unstructured":"Colby SL, Ortman JM. The Baby Boom Cohort in the United States: 2012 to 2060. Current Population Reports, P25-1141. Washington, DC: US Census Bureau; May 2014. available at https:\/\/www.census.gov\/content\/dam\/Census\/library\/publications\/2014\/demo\/p25-1141.pdf. Accessed October 11, 2016."},{"key":"hoi190039r19","unstructured":"US Food and Drug Administration. FDA Drug Safety Communication: new restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. https:\/\/www.fda.gov\/drugs\/drugsafety\/ucm256581.htm. Updated December 15, 2011. Accessed December 13, 2013."}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2738104\/jamacardiology_bach_2019_oi_190039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T11:01:29Z","timestamp":1568804489000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2738104"}},"subtitle":["A Secondary Analysis of a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2019.2306","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.736247574.793566031","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.736247574.793564177","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.736247574.793565661","asserted-by":"object"}]},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,1]]}}}